Ficus Technology Holdings Limited
細葉榕科技控股有限公司

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 8107)

UPDATES ON DISCLAIMER OF OPINION ON GOING CONCERN AS SET OUT IN THE ANNUAL REPORT FOR THE YEAR ENDED 31 DECEMBER 2025

This announcement is made by Ficus Technology Holdings Limited (the "**Company**", together with its subsidiaries, the "**Group**") to provide updates in relation to the disclaimer of opinion solely on going concern issue (the "**Disclaimer of Opinion**") as set out in the annual report of the Company for the year ended 31 December 2025 (the "**Annual Report**"). Unless otherwise specified, capitalised terms used herein shall have the same meaning as defined in the Annual Report.

The Company wishes to provide the following progress updates on the Company's Plans and Measures for the period from the date of publication of the Annual Report up to the date of this announcement.

As at the date of this announcement,

(i) the Group continues to implement cost control measures, closely monitoring, controlling and reducing operational and administrative costs and expenses to minimize cash outflows;

(ii) the Group continues to explore suitable business development opportunities with a view to broadening the Group's revenue streams. In this regard, the Group has made tangible progress, turning previous business potentials into implementation. The Group successfully bid for the Shenzhen Sports Lottery Administration Centre Promotional Gifts Procurement Services Project (the "**Project**") on 24 June 2026, as disclosed in the Company's announcement dated 25 June 2026, which marks the Group's entry into 832 Platform-related government procurement. The first batch order under the Project, with an aggregate consideration of approximately RMB1.89 million, has been placed in July. The Group also entered into an Annual Procurement Framework Agreement with Zhejiang Tianliang Biomedical Technology Co., Ltd. on 9 July 2026, as disclosed in the Company's announcement dated 13 July 2026, which expands the Group's supply chain service application to cover a wider range of products. The first purchase order of Class II medical devices with an aggregate consideration of RMB4.4 million was received thereunder on the same date. The Group intends to continue pursuing other suitable business development opportunities that can contribute to the diversification and expansion of its revenue streams;

(iii) the Company is pursuing a range of capital raising alternatives to improve the financial position of the Group. These include an equity line of credit facility of up to US$25 million (equivalent to approximately HK$195 million) with the Investor pursuant to the Subscription Agreement dated 3 March 2025 (as supplemented by the Supplemental Agreement dated 11 June 2025) and other fund raising exercises such as share placement, rights issues or others. As at the date of this announcement, no drawdown has been made under the facility. The Company is in the process of completing the technical and procedural arrangements required for potential utilization of the facility with its professional advisers. The Group does not currently face an immediate liquidity need that would necessitate drawing down the facility. The Directors continue to evaluate the implementation of these alternatives under the present market conditions;

(iv) the directors and/or controlling shareholders have provided financial support to the Group to meet its financial obligations; and

(v) the Group continues to maintain normal business relationships with its major suppliers and customers to ensure the continuity of its operations.

The Company will publish announcement(s) for the updates regarding the Disclaimer of Opinion as and when appropriate in accordance with the Listing Rules and/or as required by the Stock Exchange.

By order of the Board
Ficus Technology Holdings Limited
Mr. Chan Ting
Chairman and Executive Director

Hong Kong, 30 July 2026

As at the date of this announcement, the Board comprises (i) five executive Directors, namely, Mr. Chan Ting (Chairman), Ms. Chan Siu Sarah, Ir Prof. Young Andrew Meng Cheung, Mr. Wen Yuan and Mr. Fung King Him Daniel; and (ii) three independent non-executive Directors, namely Dr. Liu Ta-pei, Mr. Choi Man On and Mr. Jan Ting Wai.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief, the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the "Latest Listed Company Information" page on the website of the Stock Exchange of Hong Kong Limited at www.hkexnews.hk for a minimum period of 7 days from the date of its publication and on the Company's website at www.ficustech.com.